Opinion

Video

Introduction and Current Landscape of HER2 in NSCLC

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.

Video content above is prompted by the following:

  1. Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms.
  2. (Bazhenova) Describe the difference between HER2 mutation and HER2 expression.
  3. (Kim) Provide an overview of the current HER2-directed therapies (fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine) available and how they’re recommended in the NCCN guidelines.
Related Videos
1 KOL is featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Rachel Dalthorp, MD
1 KOL is featured in this series.
Related Content
Definition of opioids | Image Credit: Feng Yu - stock.adobe.com
September 30th 2024

Opioids, Benzodiazepines Linked to Higher Mortality in Older Patients With COPD

Brooke McCormick
A study found that opioid use, with or without benzodiazepines, significantly increases long-term mortality risk in patients with chronic obstructive pulmonary disease (COPD) over the age of 60 years.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Screenshot of Akshay Desai, MD, of Brigham & Women’s Hospital, during a video interview
September 29th 2024

Efficacy of Finerenone Around Recent Worsening Heart Failure

Laura Joszt, MA
Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Human lungs on scientific background | Image Credit: © Crystal light - stock.adobe.com
September 27th 2024

Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH

Gwen Mergian
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.
FDA approval stamp | Image Credit: cartoon - stock.adobe.com
September 27th 2024

FDA Approves Dupilumab as First Biologic Treatment for COPD

Brooke McCormick
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo